Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium, 42940 [2018-18301]

Download as PDF 42940 Federal Register / Vol. 83, No. 165 / Friday, August 24, 2018 / Notices notice was published in the Federal Register pursuant to Section 6(b) of the Act on June 19, 2018 (83 FR 28446). DEPARTMENT OF JUSTICE daltland on DSKBBV9HB2PROD with NOTICES Antitrust Division Department of Justice, 145 N Street NE, Suite 10W.121, Washington, DC 20530. Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium Suzanne Morris, Chief, Premerger and Division Statistics Unit Antitrust Division. Dated: August 15, 2018. Katharine Sullivan, Acting Director, Office on Violence Against Women. [FR Doc. 2018–18301 Filed 8–23–18; 8:45 am] [FR Doc. 2018–18336 Filed 8–23–18; 8:45 am] Notice is hereby given that, on August 3, 2018, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Medical CBRN Defense Consortium (‘‘MCDC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Novici Biotech LLC, Vacaville, CA; GigaGen Inc., San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Public Health Vaccines, LLC, Cambridge, MA; Kaleo, Inc., Richmond, VA; Sequoia Consulting Group, LLC, Solana Beach, CA; Inflammatix Inc., Burlingame, CA; Nano Terra, Inc., Cambridge, MA; Tech62, Fairfax, VA; Universal Stabilization Technologies, Inc., San Diego, CA; Southern Research Institute, Birmingham, AL; Adapt Pharma, Inc., Radnor, PA; Talis Biomedical Corporation, Chicago, IL; University of Maryland, College Park, MD; Inovio Pharmaceuticals, Plymouth Meeting, PA; Spectral Platforms, Monrovia, CA; BDO USA LLP, Mclean, VA; PharmaJet, Golden, CO; Consegna Pharma Inc., Pittsburgh, PA; and Tiba Biotech LLC, Cambridge, MA, have been added as parties to this venture. Also, MaxCyte, Inc., Gaithersburg, MD; Shield Analysis Technology, LLC, Manassas, VA; Kineta, Inc., Seattle, WA; and Pertaton (previously Harris Corp), Herndon, VA, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership. On November 13, 2015, MCDC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on January 6, 2016 (81 FR 513). The last notification was filed with the Department on May 14, 2018. A BILLING CODE 4410–11–P BILLING CODE 4410–FX–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE VerDate Sep<11>2014 19:17 Aug 23, 2018 Jkt 244001 Office on Violence Against Women Office on Violence Against Women, United States Department of Justice ACTION: Notice of Charter renewal. AGENCY: Pursuant to the Federal Advisory Committee Act (FACA), as amended (5 U.S.C. App.2), and Title IX of the Violence Against Women Act of 2005 (VAWA 2005), the Attorney General has determined that the renewal of the Task Force on Research on Violence Against American Indian and Alaska Native Women (hereinafter ‘‘the Task Force’’) is necessary and in the public interest and will provide information that will assist the National Institute of Justice (NIJ) to develop and implement a program of research on violence against American Indian and Alaska Native women, including domestic violence, dating violence, sexual assault, stalking, and murder. The program of research will evaluate the effectiveness of the Federal, state, and tribal response to violence against Indian women and will propose recommendations to improve these responses. Title IX of VAWA 2005 also required the Attorney General to establish a Task Force to assist NIJ with development of the research study and the implementation of the recommendations. The Attorney General, acting through the Director of the Office on Violence Against Women, originally established the Task Force on March 31, 2008. The Charter to renew the Task Force was filed with Congress on July 20, 2018. The Task Force is comprised of representatives from national tribal domestic violence and sexual assault nonprofit organizations, tribal governments, and national tribal organizations. Task Force members, with the exception of travel and per diem for official travel, shall serve without compensation. The Director of the Office on Violence Against Women shall serve as the Designated Federal officer for the Task Force. FOR FURTHER INFORMATION CONTACT: Sheriann C. Moore, Deputy Director for Tribal Affairs, Office on Violence Against Women, United States PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 [CPCLO Order No. 05–2018] Privacy Act of 1974; Systems of Records Criminal Division, United States Department of Justice. ACTION: Notice of a new system of records. AGENCY: Pursuant to the Privacy Act of 1974 and Office of Management and Budget (OMB) Circular No. A–108, notice is hereby given that the Criminal Division, a component within the United States Department of Justice (DOJ or Department), has established a new system of records titled ‘‘Gambling Device Registration System Records,’’ JUSTICE/CRM–030. The Criminal Division proposes to establish this system of records to manage gambling device registration forms in accordance with the Gambling Devices Act of 1962. DATES: In accordance with 5 U.S.C. 552a(e)(4) and (11), this notice is effective upon publication, subject to a 30-day period in which to comment on the routine uses, as described below. Please submit any comments by September 24, 2018. ADDRESSES: The public, OMB, and Congress are invited to submit any comments by mail to the United States Department of Justice, Office of Privacy and Civil Liberties, ATTN: Privacy Analyst, National Place Building, 1331 Pennsylvania Avenue NW, Suite 1000, Washington, DC 20530; by facsimile at 202–307–0693; or by email at privacy.compliance@usdoj.gov. To ensure proper handling, please reference the above CPCLO Order No. on your correspondence. FOR FURTHER INFORMATION CONTACT: Amanda Marchand Jones, Chief, FOIA/ PA Unit, Criminal Division, Suite 1127, 1301 New York Avenue NW, Washington, DC 20530; phone at (202) 616–0307; facsimile at (202) 514–6117. SUPPLEMENTARY INFORMATION: The Gambling Devices Act of 1962, 15 U.S.C. 1171–1178, requires any person or entity engaged in activities involving gambling devices, their subassemblies, or constituent parts, to register annually with the Attorney General. Registration SUMMARY: E:\FR\FM\24AUN1.SGM 24AUN1

Agencies

[Federal Register Volume 83, Number 165 (Friday, August 24, 2018)]
[Notices]
[Page 42940]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-18301]



[[Page 42940]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium

    Notice is hereby given that, on August 3, 2018, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense Consortium 
(``MCDC'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing changes in 
its membership. The notifications were filed for the purpose of 
extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, Novici Biotech LLC, Vacaville, CA; GigaGen Inc., San 
Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; 
Public Health Vaccines, LLC, Cambridge, MA; Kaleo, Inc., Richmond, VA; 
Sequoia Consulting Group, LLC, Solana Beach, CA; Inflammatix Inc., 
Burlingame, CA; Nano Terra, Inc., Cambridge, MA; Tech62, Fairfax, VA; 
Universal Stabilization Technologies, Inc., San Diego, CA; Southern 
Research Institute, Birmingham, AL; Adapt Pharma, Inc., Radnor, PA; 
Talis Biomedical Corporation, Chicago, IL; University of Maryland, 
College Park, MD; Inovio Pharmaceuticals, Plymouth Meeting, PA; 
Spectral Platforms, Monrovia, CA; BDO USA LLP, Mclean, VA; PharmaJet, 
Golden, CO; Consegna Pharma Inc., Pittsburgh, PA; and Tiba Biotech LLC, 
Cambridge, MA, have been added as parties to this venture.
    Also, MaxCyte, Inc., Gaithersburg, MD; Shield Analysis Technology, 
LLC, Manassas, VA; Kineta, Inc., Seattle, WA; and Pertaton (previously 
Harris Corp), Herndon, VA, have withdrawn as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, MCDC filed its original notification pursuant 
to Section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to Section 6(b) of the Act on 
January 6, 2016 (81 FR 513).
    The last notification was filed with the Department on May 14, 
2018. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on June 19, 2018 (83 FR 28446).

Suzanne Morris,
Chief, Premerger and Division Statistics Unit Antitrust Division.
[FR Doc. 2018-18301 Filed 8-23-18; 8:45 am]
 BILLING CODE 4410-11-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.